ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GDR Genedrive Plc

5.375
-0.75 (-12.24%)
Last Updated: 12:44:58
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Genedrive Plc LSE:GDR London Ordinary Share GB00B1VKB244 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.75 -12.24% 5.375 5.00 5.75 6.25 5.125 6.25 2,495,017 12:44:58
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 55k -5.15M -0.0447 -1.20 6.18M

Genedrive PLC Additional Listing of Shares (8702R)

19/06/2018 11:18am

UK Regulatory


Genedrive (LSE:GDR)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Genedrive Charts.

TIDMGDR

RNS Number : 8702R

Genedrive PLC

19 June 2018

For release: 19 June 2018

genedrive plc ("genedrive" or the "Company")

Additional Listing of Shares

Genedrive plc announces that it has issued 93,669 ordinary 1.5p shares in the capital of the Company ("Ordinary Shares") to settle shares owing under the Epistem Share Incentive Plan.

Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 25 June 2018. The Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.

Following admission, the Company's issued share capital will comprise 18,783,115 Ordinary Shares and each Ordinary Share carries one vote. There are no Ordinary Shares held in treasury and accordingly, the total number of voting rights is 18,873,115. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

- Ends -

For further details please contact:

genedrive plc

David Budd: CEO +44 (0)161 989 0245

Matthew Fowler: CFO

Peel Hunt LLP

James Steel +44 (0)207 418 8900

Oliver Jackson

Consilium Strategic Communications

Chris Gardner +44 (0)203 709 5700

Matthew Neal

Laura Thornton

genedrive@consilium-comms.com

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive(R) HCV-ID test has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive(R) platform in the EMEA and SE Asia (ex India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive(R) HCV ID Kit and Genedrive(R) platform in India.

Further details can be found at: www.genedriveplc.com and www.genedrive.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ALSUKARRWNANAAR

(END) Dow Jones Newswires

June 19, 2018 06:18 ET (10:18 GMT)

1 Year Genedrive Chart

1 Year Genedrive Chart

1 Month Genedrive Chart

1 Month Genedrive Chart

Your Recent History

Delayed Upgrade Clock